68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer
Targeting Delta-like Ligand 3 (DLL3) With 68Ga-PFD3 PET/CT for the Diagnosis and Assessment of Small Cell Lung Cancer (SCLC)
Peking University First Hospital
30 participants
Jun 1, 2025
INTERVENTIONAL
Conditions
Summary
This study aims to investigate and evaluate the safety and performance of a novel probe, PFD3, for the diagnosis and assessment of patients with small cell lung cancer (SCLC).
Eligibility
Inclusion Criteria4
- Adults.
- Histologically confirmed small cell lung cancer (SCLC).
- At least one measurable lesion ≥1 cm in diameter (primary tumor, metastatic lesion, or involved lymph node) confirmed by standard imaging modalities.
- Laboratory tests (complete blood count and biochemical analysis) completed within 4 weeks prior to enrollment.
Exclusion Criteria6
- Pregnancy.
- Breastfeeding.
- Acute psychiatric disorders.
- Inability to undergo PET scanning (e.g., due to claustrophobia, weight limits, or other medical contraindications).
- Inability to complete the study procedures as anticipated.
- Prior therapy targeting DLL3.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Based on individual clinical circumstances, eligible patients will undergo sequential \[18F\]FDG PET/CT and \[68Ga\]Ga-PFD3 PET/CT scans within one week.
Based on individual clinical circumstances, eligible patients will undergo sequential \[18F\]FDG PET/CT and \[68Ga\]Ga-PFD3 PET/CT scans within one week.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07508852